ストックスクリーナーアプリを入手
71.80
2.72%
-2.01
アフターアワーズ：
71.80
前日終値:
$73.81
開ける：
$73.67
24時間の取引高:
188.33K
Relative Volume:
0.35
時価総額：
$3.06B
収益：
$451.36M
当期純損益:
$-66.42M
株価収益率:
-44.60
EPS:
-1.6097
ネットキャッシュフロー:
$-22.31M
1週間 パフォーマンス:
-0.13%
1か月 パフォーマンス:
+5.65%
6か月 パフォーマンス:
-4.20%
1年 パフォーマンス:
+46.17%
1日の値動き範囲:
$71.54
$74.39
1週間の範囲:
$70.14
$74.39
52週間の値動き範囲:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
71.80 | 3.14B | 451.36M | -66.42M | -22.31M | -1.6097 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-27 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
Tarsus to receive $15M milestone after China approves TP-03 eye therapy - MSN
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses (NASDAQ:TARS) - Seeking Alpha
Published on: 2026-04-13 13:14:16 - baoquankhu1.vn
(TARS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Published on: 2026-04-08 15:20:10 - baoquankhu1.vn
Aug Rallies: Can Tarsus Pharmaceuticals Inc benefit from deglobalization2026 Update & Stepwise Trade Signal Guides - baoquankhu1.vn
Analyst Calls: Is Tarsus Pharmaceuticals Inc still a buy after recent gains2026 Market Trends & Low Risk High Reward Ideas - baoquankhu1.vn
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial - Sahm
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history - Yahoo Finance UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
JPMorgan Chase & Co. Sells 63,420 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins - Sahm
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors - Yahoo Finance
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Price-Driven Insight from (TARS) for Rule-Based Strategy - Stock Traders Daily
TARS Technical Analysis & Stock Price Forecast - Intellectia AI
Tarsus Pharmaceuticals (TARS) Initiates Phase 2 Trial for Lyme D - GuruFocus
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease. - Bitget
Biopharmaceutical company Tarsus Pharmaceuticals, Inc. announced that its innovative oral tablet TP-05 (lotilaner) for the potential prevention of Lyme disease has dosed the first subject in the Phase 2 clinical trial "Calliope". - Bitget
Tarsus Doses First Participant in Calliope, A Phase 2 - GlobeNewswire
First patient dosed in 700-person study to prevent Lyme disease - Stock Titan
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Published on: 2026-03-30 08:36:12 - baoquankhu1.vn
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors - Sahm
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent - Stock Titan
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst - MarketBeat
Mizuho raises Tarsus Pharmaceuticals stock price target on China approval By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - marketbeat.com
Can Tarsus Pharmaceuticals Inc maintain sales growth2026 Setups & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - AOL.com
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - The Motley Fool
Tarsus earns $15M milestone on China approval of eye drug By Investing.com - Investing.com South Africa
Tarsus earns $15M milestone on China approval of eye drug - Investing.com Canada
William Blair reiterates Outperform on Tarsus Pharmaceuticals stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals shares rise on China drug approval milestone By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (TARS) Reaches $15M Milestone After TP-03 Approval in China - GuruFocus
Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China - Quiver Quantitative
China clears first Demodex blepharitis treatment for 40 million people - Stock Titan
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Bitget
LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS) - The Globe and Mail
TARS SEC FilingsTarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(TARS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - msn.com
Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $2,364,904, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):